Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine

Abstract

Introduction No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV). Patients and Methods AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues. Results Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988–2002) and in the nationwide population-based cohort study of Denmark (1999–2007). Conclusion Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.

Successful monotherapy with autologous formalin‐fixed tumor vaccine for a Stage IV uterine cancer patient who rejected rational chemotherapy and immune checkpoint inhibitor treatment

“…To the best of our knowledge, with the exception of AFTV injections, monotherapy of Stage IV carcinoma with cancer vaccines has yielded poor results. AFTV made from resected formalin-fixed and paraffin-embedded autologous tumor tissue has been effective in glioblastoma, [1][2][3][4] bone-metastatic triple-negative breast cancer, 5,6 upper tract urothelial carcinoma, 7 advanced hepatocyte carcinoma, 8,9 malignant histiocytoma, 10 peritoneal serous carcinomas recurrent after chemotherapy, 11 gallbladder cancer, 12 advanced colon cancer, 12 and uterine cervical small cell carcinoma. 13 Almost all of these tumors at advanced stages are known to be refractory to standard chemotherapy and immune-checkpoint inhibitors.…”